METABOLIC DISORDERS
Periprosthetic bone loss post-total hip arthroplasty mitigated by bisphosphonate therapy
J Orthop Surg Res. 2018 Sep 4;13(1):225. doi: 10.1186/s13018-018-0918-712 randomized controlled trials were included in this meta-analysis which sought to evaluate the effect of bisphosphonate therapy in reducing loss of periprosthetic bone mineral density after total hip arthroplasty. In pooled analyses, reduction of periprosthetic bone mineral density was smaller among BP groups compared to control groups within 1 year of surgery, at 2-4 years after surgery, and at 5 or more years after surgery. However, the effect was largely impacted by the efficacy of third generative BPs. In subgroup analysis, third generation BPs demonstrated a significant effect versus control at each of 1 year, 2-4 years, and 5 or more years after surgery, whereas first and second generation BPs demonstrated a significant effect versus control groups at only 1 year after surgery.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
